Baricitinib-induced paradoxical psoriasis
J Eur Acad Dermatol Venereol
.
2020 Aug;34(8):e391-e393.
doi: 10.1111/jdv.16293.
Epub 2020 Mar 6.
Authors
J Di Domizio
1
,
J Castagna
2
,
M P Algros
3
,
C Prati
4
,
C Conrad
1
,
M Gilliet
1
,
D Wendling
4
,
F Aubin
2
Affiliations
1
Department of Dermatology, Lausanne University Hospital CHUV, Lausanne, Switzerland.
2
Department of Dermatology, UMR Inserm 1098, Besançon University Hospital, University of Bourgogne Franche Comté, Besançon, France.
3
Deparment of Pathology, University Hospital, Besançon, France.
4
Deparment of Rheumatology, UMR Inserm 1098, Besançon University Hospital, University of Bourgogne Franche Comté, Besançon, France.
PMID:
32052886
DOI:
10.1111/jdv.16293
No abstract available
Publication types
Letter
MeSH terms
Azetidines* / adverse effects
Humans
Psoriasis* / chemically induced
Psoriasis* / drug therapy
Purines
Pyrazoles
Sulfonamides / adverse effects
Substances
Azetidines
Purines
Pyrazoles
Sulfonamides
baricitinib